Literature DB >> 25945007

Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.

Makoto Meguro1, Toru Mizuguchi1, Toshihiko Nishidate1, Kenji Okita1, Masayuki Ishii1, Shigenori Ota1, Tomomi Ueki1, Emi Akizuki1, Koichi Hirata1.   

Abstract

AIM: To clarify the utility of using des-γ-carboxy prothrombin (DCP) and α-fetoprotein (AFP) levels to predict the prognosis of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) and the hepatitis C virus (HCV) infections.
METHODS: A total of 205 patients with HCC (105 patients with HBV infection 100 patients with HCV infection) who underwent primary hepatectomy between January 2004 and May 2012 were enrolled retrospectively. Preoperative AFP and DCP levels were used to create interactive dot diagrams to predict recurrence within 2 years after hepatectomy, and cutoff levels were calculated. Patients in the HBV and HCV groups were classified into three groups: a group with low AFP and DCP levels (LL group), a group in which one of the two parameters was high and the other was low (HL group), and a group with high AFP and DCP levels (HH group). Liver function parameters, the postoperative recurrence-free survival rate, and postoperative overall survival were compared between groups. The survival curves were compared by log-rank test using the Kaplan-Meier method. Multivariate analysis using a Cox forward stepwise logistic regression model was conducted for a prognosis.
RESULTS: The preoperative AFP cutoff levels for recurrence within 2 years after hepatectomy in the HBV and HCV groups were 529.8 ng/mL and 60 mAU/mL, respectively; for preoperative DCP levels, the cutoff levels were 21.0 ng/mL in the HBV group and 67 mAU/mL in the HCV group. The HBV group was significantly different from the other groups in terms of vascular invasion, major hepatectomy, volume of intraoperative blood loss, and surgical duration. Significant differences were found between the LL group, the HL group, and the HH group in terms of both mean disease-free survival time (MDFST) and mean overall survival time (MOST): 64.81 ± 7.47 vs 36.63 ± 7.62 vs 18.98 ± 6.17 mo (P = 0.001) and 85.30 ± 6.55 vs 59.44 ± 7.87 vs 46.57 ± 11.20 mo (P = 0.018). In contrast, the HCV group exhibited a significant difference in tumor size, vascular invasion, volume of intraoperative blood loss, and surgical duration; however, no significant difference was observed between the three groups in liver function parameters except for albumin levels. In the LL group, the HL group, and the HH group, the MDFST was 50.09 ± 5.90, 31.01 ± 7.21, and 14.81 ± 3.08 mo (log-rank test, P < 0.001), respectively, and the MOST was 79.45 ± 8.30, 58.82 ± 7.56, and 32.87 ± 6.31 mo (log-rank test, P < 0.001), respectively.
CONCLUSION: In the HBV group, the prognosis was poor when either AFP or DCP levels were high. In the HCV group, the prognosis was good when either or both levels were low; however, the prognosis was poor when both levels were high. High levels of both AFP and DCP were an independent risk factor associated with tumor recurrence in the HBV and HCV groups. The relationship between tumor marker levels and prognosis was characteristic to the type of viral hepatitis.

Entities:  

Keywords:  Des-γ-carboxy prothrombin; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; α-fetoprotein

Mesh:

Substances:

Year:  2015        PMID: 25945007      PMCID: PMC4408466          DOI: 10.3748/wjg.v21.i16.4933

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation.

Authors:  Ken Shirabe; Akinobu Taketomi; Kazutoyo Morita; Yuji Soejima; Hideaki Uchiyama; Hiroto Kayashima; Mizuki Ninomiya; Takeo Toshima; Yoshihiko Maehara
Journal:  Clin Transplant       Date:  2011-04-25       Impact factor: 2.863

2.  Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.

Authors:  Young Eun Chon; Gi Hong Choi; Myoung Ha Lee; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kyung Sik Kim; Jin Sub Choi; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  Int J Cancer       Date:  2012-03-28       Impact factor: 7.396

Review 3.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

4.  Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Takuro Niinomi; Takanori Ito; Yuji Kaneoka; Atsuyuki Maeda
Journal:  J Hepatol       Date:  2012-07-20       Impact factor: 25.083

5.  Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma.

Authors:  Gia L Tyson; Zhigang Duan; Jennifer R Kramer; Jessica A Davila; Peter A Richardson; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2011-08-04       Impact factor: 11.382

6.  Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus.

Authors:  Takashi Kumada; Hidenori Toyoda; Seiki Kiriyama; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Toshifumi Tada; Junko Tanaka; Hiroshi Yoshizawa
Journal:  J Gastroenterol       Date:  2010-12-07       Impact factor: 7.527

7.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.

Authors:  Jong Young Choi; Seung Won Jung; Hee Yeon Kim; Myungshin Kim; Yonggoo Kim; Dong Goo Kim; Eun-Jee Oh
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

9.  As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3β pathway.

Authors:  L Liu; Z Dong; J Liang; C Cao; J Sun; Y Ding; D Wu
Journal:  Oncogene       Date:  2013-07-01       Impact factor: 9.867

Review 10.  Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region.

Authors:  Mi Na Kim; Beom Kyung Kim; Kwang-Hyub Han
Journal:  J Gastroenterol       Date:  2013-03-06       Impact factor: 7.527

View more
  20 in total

Review 1.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

2.  HCC with low- and normal-serum alpha-fetoprotein levels.

Authors:  Brian I Carr; Hikmet Akkiz; Oguz Üsküdar; Kendal Yalçın; Vito Guerra; Sedef Kuran; Ümit Karaoğullarından; Engin Altıntaş; Ayşegül Özakyol; Salih Tokmak; Tuğsan Ballı; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Anıl Delik; Burcu Arslan; Figen Doran; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

3.  Hepatectomy Combined with Diaphragmatic Resection for Hepatocellular Carcinoma with Diaphragmatic Involvement: A Propensity Score-Matched Analysis.

Authors:  Tatsuya Orimo; Toshiya Kamiyama; Kenji Wakayama; Shingo Shimada; Akihisa Nagatsu; Yoh Asahi; Yuzuru Sakamoto; Hirofumi Kamachi; Akinobu Taketomi
Journal:  Ann Surg Oncol       Date:  2020-06-25       Impact factor: 5.344

4.  Different Risk Factors for Early and Late Recurrence After Curative Resection of Hepatocellular Carcinoma.

Authors:  Suk Kyun Hong; Xue-Li Jin; Sanggyun Suh; Su Young Hong; Kwangpyo Hong; Eui Soo Han; Jeong-Moo Lee; YoungRok Choi; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh
Journal:  World J Surg       Date:  2021-09-17       Impact factor: 3.352

5.  Multiplication of Tumor Volume by Two Tumor Markers Is a Post-Resection Prognostic Predictor for Solitary Hepatocellular Carcinoma.

Authors:  Shin Hwang; Gi-Won Song; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Dong-Hwan Jung; Gil-Chun Park; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2016-06-16       Impact factor: 3.452

6.  Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy.

Authors:  Kei Moriya; Tadashi Namisaki; Hiroaki Takaya; Kosuke Kaji; Hideto Kawaratani; Naotaka Shimozato; Yasuhiko Sawada; Akitoshi Douhara; Shinya Sato; Masanori Furukawa; Koh Kitagawa; Takemi Akahane; Hitoshi Yoshiji
Journal:  J Clin Med       Date:  2021-02-07       Impact factor: 4.241

7.  MRI Features of Hepatic Sarcomatoid Carcinoma Different From Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Hongbin Zhang; Siyuan Chai; Lintao Chen; Yubizhuo Wang; Yongna Cheng; Quan Fang; Guosen Wu; Xiangming Wang; Wenjie Liang; Wenbo Xiao
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

8.  Des-γ-Carboxyprothrombin Plasma Level in Diagnosis of Hepatocellular Carcinoma in a Chinese Population Undergoing Surgery.

Authors:  Xiaobin Feng; Peipei Song; Ping Bie; Peng Jiang; Kuansheng Ma; Xiaowu Li; Shuguang Wang; Zhigang Wang; Wei Tang; Shuguo Zheng
Journal:  Med Sci Monit       Date:  2016-05-17

Review 9.  Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.

Authors:  Xiao-Xiao Ding; Qing-Ge Zhu; Shi-Ming Zhang; Lei Guan; Ting Li; Lei Zhang; Shi-Yang Wang; Wan-Li Ren; Xue-Mei Chen; Jing Zhao; Song Lin; Zhi-Zhen Liu; Yan-Xia Bai; Bing He; Hu-Qin Zhang
Journal:  Oncotarget       Date:  2017-06-06

10.  Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection.

Authors:  Narongsak Rungsakulkij; Wikran Suragul; Somkit Mingphruedhi; Pongsatorn Tangtawee; Paramin Muangkaew; Suraida Aeesoa
Journal:  Infect Agent Cancer       Date:  2018-06-08       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.